| ABSTRACT Objective:To observe the clinical effects and safety of metformin combined with ethinylestradiol and cyproterone acetate on the treatment of polycystic ovary syndrome (PCOS). Methods:140 patients with PCOS enrolled in our station were divided into control group (70 cases) and study group (70 cases) at random. The control group received ethinylestradiol and cyproterone acetate tablets, the study group received ethinylestradiol and cyproterone acetate tablets and metformin. All treated for 3 months. The fasting blood glucose (FBG), fasting blood insulin (FINS), body mass index (BMI), waist hip ratio (WHR), the level of hormone and ultrasound examination results were compared; the adverse reactions, ovulation rate and pregnancy rate were recorded. Results:After treatment of 3 months, the level of luteinizing hormone (LH), prolactin (PRL), testosterone (T) decreased, the average number of follicle and the average volume of ovary were reduced significantly（P<0.05）, WHR of control group increased（P<0.05）, endometrial thickness of study group decreased (P<0.05). Compared with control group, the WHR, FINS, the level of LH and T, endometrial thickness, the average number of follicle and the average volume of ovary of study group were decreased greatly (P<0.05); the other indexes such as BMI, FBG, adverse reactions, ovulation rate and pregnancy rate were similar between two groups (P>0.05). Conclusion:Metformin combined with ethinylestradiol and cyproterone acetate tablets were more effective than ethinylestradiol and cyproterone acetate tablets single used, and was an appropriate alternative for PCOS. |
